WO2001027135A3 - Regulators of the hedgehog pathway, compositions and uses related thereto - Google Patents
Regulators of the hedgehog pathway, compositions and uses related thereto Download PDFInfo
- Publication number
- WO2001027135A3 WO2001027135A3 PCT/US2000/028479 US0028479W WO0127135A3 WO 2001027135 A3 WO2001027135 A3 WO 2001027135A3 US 0028479 W US0028479 W US 0028479W WO 0127135 A3 WO0127135 A3 WO 0127135A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- regulators
- compositions
- function
- hedgehog pathway
- uses related
- Prior art date
Links
- 0 *C1CC2=CCC(C(CC3N(C*(*)CCC4)C4*(*)CC33)C3(*)C(*)C3)C3C2(*)CC1 Chemical compound *C1CC2=CCC(C(CC3N(C*(*)CCC4)C4*(*)CC33)C3(*)C(*)C3)C3C2(*)CC1 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001530353A JP5420128B2 (en) | 1999-10-13 | 2000-10-13 | Hedgehog pathway modulators and related compositions and methods of use |
AU12045/01A AU781524B2 (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
IL14906900A IL149069A0 (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
CA002386190A CA2386190C (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
EP00973544A EP1235851B1 (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
DE60028411T DE60028411T2 (en) | 1999-10-13 | 2000-10-13 | CONNECTIONS FOR REGULATING THE HEDGEHOG SIGNAL PATH, COMPOSITIONS AND USES THEREOF |
IL149069A IL149069A (en) | 1999-10-13 | 2002-04-10 | Regulators of the hedgehog pathway, compositions and uses related thereto |
AU2006202843A AU2006202843B2 (en) | 1999-10-13 | 2006-07-03 | Regulators of the hedgehog pathway, compositions and uses related thereto |
IL179814A IL179814A (en) | 1999-10-13 | 2006-12-04 | Compositions comprising regulators of the hedgehog pathway for use in regulating differentiation or proliferation of cells, controlling the growth or development of pancreatic tissue and treating a hyperproliferative disorder |
IL213594A IL213594A (en) | 1999-10-13 | 2011-06-16 | Use of a veratrum-type alkaloid for preparing medicaments and an in-vitro method for inhibiting mitotic cell proliferation using said alkaloid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15921599P | 1999-10-13 | 1999-10-13 | |
US60/159,215 | 1999-10-13 | ||
US22927300P | 2000-08-30 | 2000-08-30 | |
US60/229,273 | 2000-08-30 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001027135A2 WO2001027135A2 (en) | 2001-04-19 |
WO2001027135A3 true WO2001027135A3 (en) | 2002-05-10 |
WO2001027135A9 WO2001027135A9 (en) | 2002-08-15 |
Family
ID=26855755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/028479 WO2001027135A2 (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
Country Status (9)
Country | Link |
---|---|
US (5) | US7098196B1 (en) |
EP (2) | EP1728797A3 (en) |
JP (2) | JP5420128B2 (en) |
AT (1) | ATE328002T1 (en) |
AU (2) | AU781524B2 (en) |
CA (1) | CA2386190C (en) |
DE (1) | DE60028411T2 (en) |
IL (4) | IL149069A0 (en) |
WO (1) | WO2001027135A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
WO2001027135A2 (en) | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
CA2425356C (en) * | 2000-10-13 | 2015-10-06 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
AU2002217911A1 (en) * | 2000-11-28 | 2002-06-11 | Curis, Inc. | Basal cell carcinoma cultures, methods related thereto and their use |
CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
AU2001272892B8 (en) * | 2001-07-02 | 2006-05-04 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
US20080118493A1 (en) * | 2003-07-15 | 2008-05-22 | Beachy Philip A | Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity |
US20080095761A1 (en) * | 2003-10-01 | 2008-04-24 | The Johns Hopkins University | Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis |
US20070231828A1 (en) * | 2003-10-01 | 2007-10-04 | Johns Hopkins University | Methods of predicting behavior of cancers |
US20080057071A1 (en) * | 2003-10-20 | 2008-03-06 | Watkins David N | Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer |
ZA200701535B (en) * | 2004-08-27 | 2008-12-31 | Infinity Pharmaceuticals Inc | Cyclopamine analogues and methods of use thereof |
BRPI0514444A (en) * | 2004-08-27 | 2008-06-10 | Infinity Pharmaceuticals Inc | cyclopamine analogues and methods of use of these |
WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
AU2006246923A1 (en) * | 2005-05-16 | 2006-11-23 | Island Laboratories Inc. | System and method for promoting hair growth and improving hair and scalp health |
WO2007123511A2 (en) * | 2006-03-24 | 2007-11-01 | Infinity Pharmaceuticals, Inc. | Dosing regimens for the treatment of cancer |
RU2009137014A (en) * | 2007-03-07 | 2011-04-20 | Инфинити Дискавери, Инк. (Us) | HETEROCYCLIC ANALOGUES OF CYCLOPAMINE AND METHODS OF THEIR APPLICATION |
AU2008222655B2 (en) | 2007-03-07 | 2014-03-27 | Infinity Pharmaceuticals, Inc. | Cyclopamine lactam analogs and methods of use thereof |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
US20090181997A1 (en) * | 2007-12-27 | 2009-07-16 | Grayzel David | Therapeutic cancer treatments |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009155283A2 (en) * | 2008-06-17 | 2009-12-23 | Duke University | Radiolabled cyclopamine assay for the smoothened receptor |
WO2010024930A2 (en) | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
WO2010080817A2 (en) * | 2009-01-06 | 2010-07-15 | Utah State University | Carbohydrate-cyclopamine conjugates as anticancer agents |
JP2009143963A (en) * | 2009-03-25 | 2009-07-02 | Sinan Tas | Pharmaceutical composition for treating tumor using hedgehog/smoothened signal for inhibiting apoptosis of tumor cell |
WO2010117800A2 (en) * | 2009-03-30 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Shh regulation and methods thereof |
FR2948367A1 (en) | 2009-07-24 | 2011-01-28 | Centre Nat Rech Scient | ACYL-GUANIDINE DERIVATIVES MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATHWAY |
JP6141015B2 (en) | 2009-08-05 | 2017-06-07 | インフィニティ ファーマスーティカルズ、インク. | Enzymatic transamination of cyclopamine analogues. |
KR20120099715A (en) * | 2009-11-06 | 2012-09-11 | 인피니티 파마슈티칼스, 인코포레이티드 | Oral formulations of a hedgehog pathway inhibitor |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
CN103002738A (en) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | Chemical compounds, compositions and methods for kinase modulation |
JP2013545749A (en) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
FR2967498B1 (en) | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | USE OF QUINOLINONE DERIVATIVES AS A RESEARCH TOOL |
MX347708B (en) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones. |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
JP6027610B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
FR2980477B1 (en) | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | NOVEL MODULATING COMPOUNDS OF THE HEDGEHOG PROTEIN SIGNALING PATH, THEIR MARKED FORMS, AND APPLICATIONS |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RS58023B2 (en) | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
EP2925363A4 (en) | 2012-11-29 | 2016-11-09 | Strasspharma Llc | Methods of modulating follicle stimulating hormone activity |
US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
JP2014028835A (en) * | 2013-09-18 | 2014-02-13 | Sinan Tas | Use method of cyclopamine in treatment of basal cell cancer and other tumor |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
JP6494631B2 (en) | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Colchistatin analogues and their synthesis and use |
MX2016012021A (en) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders. |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
BR112017026103B1 (en) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | TOPICAL COMPOSITIONS WITH HEDGEHOG INHIBITOR COMPOUND, TOPICAL DELIVERY SYSTEM AND THEIR USES |
EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
US20170231968A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
CN105622708B (en) * | 2016-02-14 | 2017-10-10 | 山东大学 | Treat compound of respiratory syncytial virus infection and preparation method thereof and purposes |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2018016227A (en) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Combination therapies. |
CN110894209A (en) * | 2018-09-13 | 2020-03-20 | 上海科技大学 | Smooth receptor ligand |
CN111018791B (en) * | 2019-12-20 | 2021-05-25 | 厦门蔚嘉制药有限公司 | Novel method for preparing lopinavir |
WO2021216846A2 (en) * | 2020-04-22 | 2021-10-28 | The Regents Of The University Of Michigan | Stem cell derived single-rosette brain organoids and related uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052534A1 (en) * | 1998-04-09 | 1999-10-21 | Johns Hopkins University School Of Medicine | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT280497B (en) | 1968-03-05 | 1970-04-10 | Chemie Linz Ag | Process for the production of new, unsaturated aminosteroids |
AT300214B (en) | 1970-04-24 | 1972-07-25 | Chemie Linz Ag | Process for the production of piperidyl steroids |
NZ193564A (en) | 1979-05-02 | 1985-01-31 | Aruba Pty Ltd | Steroid alkaloids from solanum sodomeum and pharmaceutical compositions |
US5028422A (en) | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
US5026882A (en) | 1988-12-23 | 1991-06-25 | Smithkline Beecham Corporation | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase |
WO1991010743A1 (en) | 1990-01-18 | 1991-07-25 | Cura Nominees Pty Ltd | Glycoalkaloids |
US5639738A (en) | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
JPH04230696A (en) | 1990-12-28 | 1992-08-19 | Sanwa Shiyouyaku Kk | New steroidal compound and carcinostatic agent |
AU659625B2 (en) | 1991-01-18 | 1995-05-25 | Clilco, Ltd. | Lice-repellant compositions |
US5466687A (en) | 1992-10-22 | 1995-11-14 | Dr. Karl Thomae Gmbh | Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation |
US5486511A (en) | 1993-05-25 | 1996-01-23 | Merrell Dow Pharmaceuticals Inc. | 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase |
CN1102993A (en) | 1993-12-21 | 1995-05-31 | 吴文才 | Method for making Chinese medicine herbs preparation by polyenzyme system |
US6057091A (en) | 1994-12-02 | 2000-05-02 | The Johns Hopkins University School Of Medicine | Method of identifying compounds affecting hedgehog cholesterol transfer |
DE19517147C2 (en) | 1995-05-10 | 1999-07-01 | Hexal Pharmaforschung Gmbh | Acyclovir preparation |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
WO1998030576A1 (en) | 1996-10-07 | 1998-07-16 | The Johns Hopkins University School Of Medicine | Novel hedgehog-derived polypeptides |
US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
TW577875B (en) | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
JP4669968B2 (en) | 1997-02-10 | 2011-04-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods for regulating hematopoiesis and angiogenesis |
US6495532B1 (en) | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
PL348667A1 (en) | 1997-06-17 | 2002-06-03 | Abbott Lab | Pyrrolidine carboxylic acid derivatives as endothelin antagonists |
US20050130922A1 (en) | 1997-06-20 | 2005-06-16 | Altaba Ariel R.I. | Method and compositions for inhibiting tumorigenesis |
AU7980098A (en) | 1997-06-20 | 1999-01-04 | Elena Y. Enioutina | Method to enhance innate immunity defense mechanisms by treatment with plan t-derived alkaloids |
US6238876B1 (en) | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US5892038A (en) | 1997-12-08 | 1999-04-06 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
US6288048B1 (en) | 1998-02-13 | 2001-09-11 | The Johns Hopkins University School Of Medicine | Cholesterol and hedgehog signaling |
US6867216B1 (en) | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
ES2233383T3 (en) | 1999-06-08 | 2005-06-16 | Lorantis Limited | THERAPEUTIC USE OF A HEDGEHOG SIGNALING ROAD IHIBITOR. |
US20050080138A1 (en) | 1999-09-16 | 2005-04-14 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2001027135A2 (en) | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
CA2388468C (en) | 1999-10-14 | 2011-01-25 | Curis, Inc. | Mediators of hedgehog signalling pathways, compositions and uses related thereto |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2001040438A2 (en) | 1999-11-30 | 2001-06-07 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US6683108B1 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
WO2001098344A2 (en) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
CU23175A1 (en) | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | LIPOSOMIC FORMULATION OF CLOBETASOL PROPIONATE |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
CA2425356C (en) | 2000-10-13 | 2015-10-06 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
JP2004534743A (en) | 2001-04-09 | 2004-11-18 | ロランティス リミテッド | Hedgehog |
CA2452152A1 (en) | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
US20050011207A1 (en) | 2003-07-14 | 2005-01-20 | Porter Kevin J. | Control of air conditioning system with limited number of discrete inputs |
KR20050037103A (en) | 2003-10-17 | 2005-04-21 | 주식회사 엘지생활건강 | Cosmetic composition for whitening of the skin |
US7390688B2 (en) | 2005-02-21 | 2008-06-24 | Casio Computer Co.,Ltd. | Semiconductor device and manufacturing method thereof |
US20100080855A1 (en) * | 2008-09-12 | 2010-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies |
-
2000
- 2000-10-13 WO PCT/US2000/028479 patent/WO2001027135A2/en active Application Filing
- 2000-10-13 DE DE60028411T patent/DE60028411T2/en not_active Expired - Lifetime
- 2000-10-13 US US09/688,076 patent/US7098196B1/en not_active Expired - Lifetime
- 2000-10-13 AT AT00973544T patent/ATE328002T1/en not_active IP Right Cessation
- 2000-10-13 EP EP06011086A patent/EP1728797A3/en not_active Withdrawn
- 2000-10-13 IL IL14906900A patent/IL149069A0/en active IP Right Grant
- 2000-10-13 AU AU12045/01A patent/AU781524B2/en not_active Expired
- 2000-10-13 JP JP2001530353A patent/JP5420128B2/en not_active Expired - Lifetime
- 2000-10-13 CA CA002386190A patent/CA2386190C/en not_active Expired - Lifetime
- 2000-10-13 EP EP00973544A patent/EP1235851B1/en not_active Expired - Lifetime
-
2002
- 2002-04-10 IL IL149069A patent/IL149069A/en unknown
-
2006
- 2006-01-23 US US11/338,503 patent/US7476661B2/en not_active Expired - Lifetime
- 2006-07-03 AU AU2006202843A patent/AU2006202843B2/en not_active Expired
- 2006-12-04 IL IL179814A patent/IL179814A/en active IP Right Grant
-
2008
- 2008-03-28 US US12/079,776 patent/US7998946B2/en not_active Expired - Fee Related
-
2011
- 2011-06-16 IL IL213594A patent/IL213594A/en active IP Right Grant
- 2011-07-05 US US13/176,297 patent/US8163719B2/en not_active Expired - Lifetime
- 2011-07-25 JP JP2011162523A patent/JP2011251991A/en active Pending
-
2012
- 2012-02-01 US US13/363,934 patent/US9440988B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052534A1 (en) * | 1998-04-09 | 1999-10-21 | Johns Hopkins University School Of Medicine | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
Non-Patent Citations (25)
Title |
---|
AKTUAL. VOPR. FARM. (1974), 2, 342-3 * |
BADRIA FARID A ET AL: "Time course and inhibition of stavaroside K, veratramine and cervine-induced hemolysis by other pregnane glycosides and Veratrum alkaloids.", PHARMAZIE, vol. 50, no. 6, 1995, pages 421 - 423, XP002166404, ISSN: 0031-7144 * |
BAGGIOLINI, E. ET AL: "Photochemical reactions. 62. Photofragmentation of O-acetyljervine", HELV. CHIM. ACTA (1971), 54(2), 429-49, XP002166406 * |
BROWN, DENNIS ET AL: "Structure-activity relation of steroid teratogens. 2. N-Substituted jervines", J. AGRIC. FOOD CHEM. (1978), 26(3), 564-6, XP002166403 * |
CELLULAR AND MOLECULAR BIOLOGY (NOISY-LE-GRAND), vol. 45, no. 5, July 1999 (1999-07-01), pages 579 - 588 * |
CHEMICAL ABSTRACTS, vol. 129, no. 18, 2 November 1998, Columbus, Ohio, US; abstract no. 228114, TEZUKA, YASUHIRO ET AL: "Two New Steroidal Alkaloids, 20-Isoveratramine and Verapatuline, from the Roots and Rhizomes of Veratrum patulum" XP002166409 * |
CHEMICAL ABSTRACTS, vol. 132, no. 21, 22 May 2000, Columbus, Ohio, US; abstract no. 276648, TEZUKA, YASUHIRO ET AL: "Anti-Helicobacter pylori activity of steroidal alkaloids obtained from three Veratrum plants" XP002166410 * |
CHEMICAL RESEARCH IN TOXICOLOGY, vol. 9, no. 2, 1996, pages 426 - 433, ISSN: 0893-228X * |
CHIANG CHIN ET AL: "Essential role for Sonic hedgehog during hair follicle morphogenesis", DEVELOPMENTAL BIOLOGY,US,ACADEMIC PRESS, NEW YORK, NY, vol. 205, no. 1, 1999, pages 1 - 9, XP002137928, ISSN: 0012-1606 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, CRAWFORD L ET AL: "A preliminary assessment of the toxic and mutagenic potential of steroidal alkaloids in transgenic mice.", XP002166417, Database accession no. PREV199598228434 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, GAFFIELD WILLIAM ET AL: "Induction of terata in hamsters by solanidane alkaloids derived from Solanum tuberosum.", XP002166416, Database accession no. PREV199698740617 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1998, INCARDONA JOHN P ET AL: "The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic hedgehog signal transduction.", XP002166415, Database accession no. PREV199800507846 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 1999 (1999-07-01), GAFFIELD WILLIAM ET AL: "A looking glass perspective: Thalidomide and cyclopamine.", XP002166414, Database accession no. PREV200000433481 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ATTA-UR-RAHMAN ET AL: "Alkaloids from Veratrum album", XP002166413, retrieved from STN Database accession no. 114:160735 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BONDARENKO, N. V. ET AL: "Chromatographic separation of jervine derivatives", XP002166412, retrieved from STN Database accession no. 76:141097 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GERASHCHENKO, G. I. ET AL: "Glucocorticosteroidal properties of several jervine derivatives", XP002166411, retrieved from STN Database accession no. 84:99345 * |
DEVELOPMENT (CAMBRIDGE), vol. 125, no. 18, 1998, pages 3553 - 3562, ISSN: 0950-1991 * |
FOOD AND CHEMICAL TOXICOLOGY, vol. 33, no. 3, 1995, pages 191 - 194, ISSN: 0278-6915 * |
J. NAT. PROD. (1998), 61(9), 1078-1081 * |
KIM SEUNG K ET AL: "Pancreas development is promoted by cyclopamine, a hedgehog signaling inhibitor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 22, 27 October 1998 (1998-10-27), Oct. 27, 1998, pages 13036 - 13041, XP002166407, ISSN: 0027-8424 * |
MASAMUNE, TADASHI ET AL: "Synthesis and nuclear magnetic resonance spectra of 22,27-imino-17,23-epoxyjervane derivatives", TETRAHEDRON (1967), 23(4), 1591-612, XP002166405 * |
PHYTOCHEMISTRY (1991), 30(1), 368-70 * |
TAIPALE, JUSSL ET AL: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", NATURE (LONDON) (2000), 406(6799), 1005-1009, XP002166408 * |
TR. VITEBSK. TEKHNOL. INST. LEGK. PROM. (1970), NO. 1, 122-3 FROM: REF. ZH., KHIM. 1971, ABSTR. NO. 3G255 * |
WAKAN IYAKUGAKU ZASSHI (1999), 16(5/6), 196-200 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9145422B2 (en) | 2006-12-28 | 2015-09-29 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9492435B2 (en) | 2006-12-28 | 2016-11-15 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001027135A3 (en) | Regulators of the hedgehog pathway, compositions and uses related thereto | |
HUP0300268A3 (en) | Herbicidal benzoylpyrazole derivatives, compositions containing the same and their use | |
AU2002313903A1 (en) | Emulsified compositions for bleaching or dyeing the hair and methods of bleaching or dyeing the hair using these emulsified compositions | |
WO2002040627A8 (en) | Stabilized liquid compositions | |
PL366799A1 (en) | Mediators of hedgehog signaling pathways, compositions and uses related thereto | |
HK1046296A1 (en) | Lubricating oil compositions and watch containing the same. | |
WO2004069152A3 (en) | Δ4,5 glycuronidase and uses thereof | |
WO2003016428A3 (en) | Triboluminescent materials and devices containing them | |
EP2348030A3 (en) | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | |
Haringsma et al. | The value of fluorescence techniques in gastrointestinal endoscopy: better than the endoscopist's eye? I: The European experience | |
AU2001262686A1 (en) | Online reservation/control system for beauticians or the like | |
Marcon et al. | The value of fluorescence techniques in gastrointestinal endoscopy-better than the endoscopist's eye? II: The North American experience | |
WO2002017919A3 (en) | Use of threo-methylphenidate compounds to enhance memory | |
AU2001275918A1 (en) | Biocide compositions and methods and systems employing same | |
MXPA05001074A (en) | Emulsified water/hydrocarbon fuel, preparation and uses thereof. | |
AU2000278051A1 (en) | Stabilized emulsion compositions | |
WO2002020823A3 (en) | Methods and compositions for visualizing and interfering with chromosomal tethering of extrachromosomal molecules | |
AU6073299A (en) | Oligonucleotide primers that destabilize non-specific duplex formation and uses thereof | |
Lorenzetti | Policymakers eye frac regulation to protect groundwater | |
WO2002062915A8 (en) | Paper products containing triboluminescent materials | |
AU2002330245A1 (en) | Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use | |
WO1999047654A3 (en) | Combination of genes for regulating flowering induction in useful and ornamental plants | |
DE29803096U1 (en) | Envelopes, envelopes, envelopes or the like protected from sight and grip. | |
AU1850701A (en) | Oil based treating or impregnation agent containing wax, and applications thereof | |
AU2001275487A1 (en) | Regulation of the p21 gene and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 149069 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2386190 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 530353 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12045/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000973544 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-129, DESCRIPTION, REPLACED BY NEW PAGES 1-129; PAGES 130-154, CLAIMS, REPLACED BY NEW PAGES130-148; PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000973544 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 12045/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000973544 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 179814 Country of ref document: IL |